# IMPase in Treatment-resistant Depression

> **NCT05117710** · PHASE1 · UNKNOWN · sponsor: **University of Oxford** · enrollment: 50 (estimated)

## Conditions studied

- Depressive Disorder, Treatment-Resistant

## Interventions

- **DRUG:** Ebselen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05117710
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-22
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-07-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05117710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05117710, "IMPase in Treatment-resistant Depression". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05117710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*